Skip to main content
SpringerLink
Log in

Diabetes and LOH Syndrome

  • Chapter
  • First Online:
Diabetes and Aging-related Complications

  • 1266 Accesses

Abstract

Age-related declines in androgen levels lead to impaired organ function known as late-onset hypogonadism (LOH). Various diseases are considered to be involved in the emergence of LOH, among which are diabetes, metabolic syndrome, arteriosclerosis, hypertension, and hyperlipidemia. Testosterone increases insulin sensitivity in muscle through functional mitochondria in muscle tissue, while lowered testosterone conversely leads to reduced glucose uptake in muscle. Diabetes mellitus (DM) and LOH are deeply interrelated diseases requiring further clinical research results in areas including diagnosis and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bagatell CJ, Bremner WJ. Androgens in men: uses and abuses. N Engl J Med. 1996;334:707–14.

    Article  CAS  PubMed  Google Scholar 

  2. Coates JM, Herbert J. Endogenous steroids and financial risk taking on a London trading floor. Proc Natl Acad Sci U S A. 2008;105:6167–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90:2618–23.

    Article  CAS  PubMed  Google Scholar 

  4. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995–2010.

    Article  CAS  PubMed  Google Scholar 

  5. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004;11:459–76.

    Article  CAS  PubMed  Google Scholar 

  6. Kuohung W, Kaiser UB. GPR54 and KiSS-1: role in the regulation of puberty and reproduction. Rev Endocr Metab Disord. 2006;7:257–63.

    Article  CAS  PubMed  Google Scholar 

  7. Morley JE, Perry HM III. Andropause: an old concept in new clothing. Clin Geriatr Med. 2003;19:507–28.

    Article  PubMed  Google Scholar 

  8. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724–31.

    Article  CAS  PubMed  Google Scholar 

  9. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–35.

    Article  CAS  PubMed  Google Scholar 

  11. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol. 2005;48:1–4.

    Article  CAS  PubMed  Google Scholar 

  12. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004;61:162–7.

    Article  PubMed  Google Scholar 

  13. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. Clin Endocrinol Metab. 2006;91:1995–2010.

    Article  CAS  Google Scholar 

  14. Shabsigh R, Katz M, Yan G, Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol. 2005;96:67 M–72 M.

    Article  CAS  Google Scholar 

  15. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol. 2009;5:673–81.

    Article  CAS  PubMed  Google Scholar 

  16. Makinen JI, Huhtaniemi I. Androgen replacement therapy in late-onset hypogonadism: current concepts and controversies. Gerontology. 2011;57:193–202.

    Article  CAS  PubMed  Google Scholar 

  17. Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013;9:414–24.

    Article  CAS  PubMed  Google Scholar 

  18. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf). 2006;65:275–81.

    Article  CAS  Google Scholar 

  19. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011;11:3204–13.

    Article  Google Scholar 

  20. Khera M, Bhattacharya RK, Blick G, et al. The effect of testosterone supplementation on depression symptom in hypogonadal men form the Testim Registry in the US (TRiUS). Aging Male. 2012;15:14–21.

    Article  CAS  PubMed  Google Scholar 

  21. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–22.

    Google Scholar 

  22. Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–36.

    Google Scholar 

  23. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematicreview and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560–75.

    Google Scholar 

  24. Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295:1288–99.

    Article  CAS  PubMed  Google Scholar 

  25. Le TN, Nestler JE, Strauss JF III, et al. Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol Metab. 2012;23:32–40.

    Article  CAS  PubMed  Google Scholar 

  26. Fan W, Yanase T, Nomura M, et al. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes. 2005;54:1000–8.

    Article  CAS  PubMed  Google Scholar 

  27. Lin HY, Xu Q, Yeh S, et al. Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes. 2005;54:1717–25.

    Article  CAS  PubMed  Google Scholar 

  28. Allan CA, et al. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17:224–32.

    Article  CAS  PubMed  Google Scholar 

  29. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27:1036–41.

    Article  CAS  PubMed  Google Scholar 

  30. Brand JS, van der Tweel I, Grobbee DE, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol. 2011;40:189–207.

    Article  PubMed  Google Scholar 

  31. Tsujimura A, Miyagawa Y, Takezawa K, et al. Is low testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men? Urology. 2013;82:814–9.

    Article  PubMed  Google Scholar 

  32. Kaushik M, et al. Cardiovascular disease and androgens: a review. Int J Cardiol. 2010;142:8–14.

    Article  PubMed  Google Scholar 

  33. Akishita M, et al. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis. 2010;210:232–6.

    Article  CAS  PubMed  Google Scholar 

  34. Corona G, et al. The role of testosterone in erectile dysfunction. Nat Rev. Urol. 2010;7:46–56.

    Article  CAS  PubMed  Google Scholar 

  35. Vigano A, et al. Male hypogonadism associated with advanced cancer: a systematic review. Lancet Oncol. 2010;11:679–84.

    Article  PubMed  Google Scholar 

  36. Ide H, Yasuda M, Nishio K, et al. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels. Anticancer Res. 2008;28:2487–92.

    PubMed  Google Scholar 

  37. Heufelder AE, Saad F, Bunck MC, et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30:726–33.

    Article  CAS  PubMed  Google Scholar 

  38. Traish AM, Haider A, Doros G, et al. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68:314–29.

    Article  CAS  PubMed  Google Scholar 

  39. Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol. 2014;2014:527470.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Dokkyo Medical University Koshigaya Hospital, 2-1-50, Minamikoshigaya, Koshigaya, Saitama, 343-8555, Japan

    Hisamitsu Ide

  2. Department of Urology, Juntendo University, Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Mayuko Kanayama & Shigeo Horie

Authors
  1. Hisamitsu Ide
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mayuko Kanayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeo Horie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigeo Horie .

Editor information

Editors and Affiliations

  1. Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Fukuoka, Japan

    Sho-ichi Yamagishi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Ide, H., Kanayama, M., Horie, S. (2018). Diabetes and LOH Syndrome. In: Yamagishi, Si. (eds) Diabetes and Aging-related Complications. Springer, Singapore. https://doi.org/10.1007/978-981-10-4376-5_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-4376-5_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-4375-8

  • Online ISBN: 978-981-10-4376-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation